Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

NCT01447914 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

NIH

Sponsor class

Conditions

Refractory Multiple Myeloma

Interventions

DRUG: Tivantinib
OTHER: Diagnostic laboratory biomarker analysis
OTHER: Questionnaire administration
PROCEDURE: Quality-of-life assessment

Sponsor

National Cancer Institute (NCI)